AbbVie gets approval for Parkinson’s treatment

SHARE AbbVie gets approval for Parkinson’s treatment
SHARE AbbVie gets approval for Parkinson’s treatment

AbbVie Inc. has won approval for a new treatment for patients with advanced Parkinson’s disease.

The North Chicago drugmaker said its drug treatment, Duopa, helps Parkinson’s patient maintain motor control. The company announced Monday the treatment has received approval from the U.S. Food and Drug Administration.

The drug treatment was approved three months ahead of the scheduled review date, Reuters reported. Duopa, which is already available in Canada, is delivered by infusion pump directly to the small intestine.

Abbvie retreats on Gilead, Anthem Deal. Buying Opportunity? [SeekingAlpha.com] Shire to acquire NPS Pharma for $5.2 billion

“There is unmet need for treatment options for patients with advanced Parkinson’s disease. As the disease advances, it can be difficult to control motor features,” said Dr. C. Warren Olanow, a professor at Mount Sinai School of Medicine and lead investigator of the drug trial. “In clinical trials, Duopa was shown to significantly reduce the amount of off time advanced Parkinson’s disease patients experienced.”

Michael Severino, AbbVie executive vice president and chief scientific officer, said the drug’s approval “is another significant milestone for AbbVie’s pipeline.”

“This advancement is important for patients with advanced Parkinson’s disease and their care teams, as it provides a new therapeutic option to help manage motor symptoms,” Severino said in a news release.

The Latest
Th survey involved 1,250 adults, which, coincidentally, is also the number of sports-media professionals in Chicago who openly are betting on the players and teams they yap and/or write about.
Which side of town does the Cubs-White Sox rivalry mean more to?
All signs point towards the Bulls and LaVine getting a deal done to make him a max player the next five years, but the unrestricted free agent wants to be wined and dined by other suitors just to hear what’s out there. That means there’s always a chance LaVine could stray.
Sneed has learned the former CPS CEO — who has made previous unsuccessful bids for mayor and governor — plans to throw his hat in the ring next week.
The Hall of Fame baseball writer died at 101, and he left an ‘imprint that’s hard to overstate.’